antidepressants

Health Secretary Robert F. Kennedy Jr. is advancing an initiative to help Americans reduce or stop antidepressant use through deprescribing efforts. Federal health officials and mental health professionals discussed clinical guidance for tapering antidepressants, reviewed European practices, and explored nonmedication options like therapy. The talks highlighted gaps in research on SSRI side effects and distinguishing them from depressive symptoms.

High temperatures can increase the risk of dizziness, dehydration, exhaustion, and other heat-related problems for people taking antidepressants. The article highlights the specific challenges faced by individuals on antidepressants during extreme heat.

Certain medications for heart disease, high blood pressure, and kidney issues can impair the body's ability to manage heat, increasing risks of dehydration, overheating, and severe health complications during heatwaves. Experts advise continuing medication use but emphasize proactive cooling measures like air conditioning, hydration, and avoiding sun exposure.

Federal prisons are required to provide hormones to transgender inmates. The government previously argued that changing medical consensus justified using psychotherapy and antidepressants instead of hormone treatment for trans inmates.

A study suggests that antidepressants and antipsychotics could serve as pain relief alternatives to opioids in emergency departments. The research reviewed non-opioid medications available at San Francisco General Hospital and analyzed existing medical literature to identify potential options for treating pain without opioids' addictive risks.

A study reviewed 26 clinical trials involving over 1,100 patients, finding that a single ketamine infusion significantly reduced severe depression symptoms within four hours and lowered suicidal thoughts within 24 hours. The analysis suggests ketamine may offer rapid relief for treatment-resistant depression, though it carries risks like dissociation and nausea.

Seaport, an antidepressant manufacturer, raised $255 million in an upsized IPO. The article also mentions BioTech USA Kft., a European food supplement manufacturer, and its production facility in Hungary.

Health authorities have issued an urgent recall of antidepressants prescribed to millions due to a manufacturing error. Patients are advised to seek immediate medical advice as a precaution.

Seaport, an antidepressant drugmaker, is seeking $212.4 million through a U.S. initial public offering (IPO). The company aims to raise capital as part of its expansion plans in the pharmaceutical sector.

A 20-year study of over 650,000 Americans with IBS found that common treatments like antidepressants and antidiarrheal drugs were linked to a small but increased risk of death over time. The findings raise concerns about the long-term safety of these medications.